LB Pharmaceuticals Financial Statements
NASDAQ: LBRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
37.22+2.61 (+7.54%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
LB Pharmaceuticals revenue and earnings
LB Pharmaceuticals reported a net loss of $25.2 million, compared with a loss of $63.1 million a year earlier. Diluted earnings per share came in at -$3.13.
Summary generated from market data by MetaCap's automated system. Methodology
LB Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 |
|---|---|---|
| Operating Expenses | 30.40M | 64.83M |
| Research & Development | 16.74M | 51.17M |
| Other Income (Expense) | 5.20M | 1.73M |
| Pretax Income | -25.20M | -63.10M |
| Income Tax | 1.00K | 1.00K |
| Net Income | -25.20M | -63.10M |
| Net Income growth (YoY) | — | — |
| EPS (Basic) | -3.13 | -176.15 |
| EPS (Diluted) | -3.13 | -176.15 |
| Shares Outstanding (Basic) | 8.05M | 358.23K |
| Shares Outstanding (Diluted) | 8.05M | 358.23K |
This table shows 2 annual periods of LB Pharmaceuticals's income statement, from FY 2025 back to FY 2024, across 10 line items including operating expenses, research & development, other income (expense). Values in USD; B = billions, M = millions. Fiscal periods follow LBRX's reporting calendar. What is a income statement?